Jagsonpal Pharmaceuticals Ltd
Tue 29/04/2025,15:48:15 | NSE : JAGSNPHARM
Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.
Market Data
Essential tool: analyze, trade, manage, decide.
Open
₹ 233.88
Previous Close
₹ 232.70
Volume
90717
Mkt Cap ( Rs. Cr)
₹1511.21
High
₹ 235.37
Low
₹ 226.95
52 Week High
₹ 328.04
52 Week Low
₹ 110.00
Book Value Per Share
₹ 29.67
Dividend Yield
0.86
Face Value
₹ 2.00
What’s Your Call?
Collective community sentiment on Jagsonpal Pharmaceuticals Ltd
Your Vote -
Buy
77.78%
Hold
11.11%
Sell
11.11%
77.78%
9 users have voted
Market Depth
How many stocks are available to buy or sell and at what prices.
Buy Order Quantity
0%
Sell Order Quantity
100%
Bid Price
Qty
0.00
0
0.00
0
0.00
0
0.00
0
0.00
0
Bid Total
0
Bid Price
Qty
227.46
930
0.00
0
0.00
0
0.00
0
0.00
0
Bid Total
930
Option Chain
Analyzes market sentiment, predicts Jagsonpal Pharmaceuticals Ltd' movement.
NO_RECORD_FOUND
News
Media spotlight triggers stock stock attention, sentiment.
-
Jagsonpal Pharma - Clarification On Significant Increase In The Volume
-
Jagsonpal Pharma - Clarification On Significant Increase In Volume Of Security Of The Company, Required By NSE
-
Jagsonpal Pharma - Spurt in Volume
-
Jagsonpal Pharma - Alteration Of Capital and Fund Raising-XBRL
-
Jagsonpal Pharma - Updates
-
Jagsonpal Pharma - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
-
Jagsonpal Pharma has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2025
-
Jagsonpal Pharma - Certificate under SEBI (Depositories and Participants) Regulations, 2018
-
Jagsonpal Pharma - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
-
Jagsonpal Pharma - Action(s) initiated or orders passed
-
Jagsonpal Pharma - Trading Window-XBRL
-
Jagsonpal Pharma - Trading Window-XBRL
-
Jagsonpal Pharma - Trading Window
-
Jagsonpal Pharma - Alteration Of Capital and Fund Raising-XBRL
-
Jagsonpal Pharma - Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agent
-
Jagsonpal Pharma - Updates
-
Jagsonpal Pharma - Updates
-
Jagsonpal Pharma - Change in Company Secretary/Compliance Officer
-
Jagsonpal Pharma - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
-
Jagsonpal Pharma - Intimation Under Regulation 30(5) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulation
-
Jagsonpal Pharma - Appointment of Company Secretary and Compliance Officer
-
Jagsonpal Pharma - Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agent
-
Jagsonpal Pharma - Change in Company Secretary/Compliance Officer
-
Jagsonpal Pharma - Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance Officer
-
Jagsonpal Pharma - Clarification In Reference To The Corporate Announcement Filed Under Regulation 30 Of SEBI (LODR) Regulati
-
Jagsonpal Pharma - General Updates
-
Jagsonpal Pharma - Announcement under Regulation 30 (LODR)-Acquisition
-
Jagsonpal Pharma - Action(s) taken or orders passed
-
Jagsonpal Pharma - Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
-
Jagsonpal Pharma - Alteration Of Capital and Fund Raising-XBRL
-
Jagsonpal Pharma - General Updates
-
Jagsonpal Pharma - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
-
Jagsonpal Pharma - Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agent
-
Jagsonpal Pharma - Updates
-
Jagsonpal Pharma - Appointment
-
Jagsonpal Pharma - Intimation Under Regulation 30(5) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulation
-
Jagsonpal Pharma - Announcement under Regulation 30 (LODR)-Change in Management
-
Jagsonpal Pharma - Analysts/Institutional Investor Meet/Con. Call Updates
-
Jagsonpal Pharma - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Key fundamentals
Evaluate the intrinsic value of Jagsonpal Pharmaceuticals Ltd stock
| Name | March-24 | March-23 | March-22 | March-21 | March-20 |
|---|---|---|---|---|---|
| Assets | 187.402 | 158.89 | 130.8556 | 128.717 | 115.6987 |
| Liabilities | 187.402 | 158.89 | 130.8556 | 128.717 | 115.6987 |
| Equity | 13.219 | 13.099 | 13.099 | 13.099 | 13.099 |
| Gross Profit | 23.067 | 34.151 | 25.7944 | 19.0785 | 8.5325 |
| Net Profit | 22.463 | 26.721 | 19.587 | 17.0583 | 7.8708 |
| Cash From Operating Activities | 35.166 | 46.655 | 5.5981 | 28.2224 | 11.247 |
| NPM(%) | 10.76 | 11.28 | 8.66 | 9.07 | 4.96 |
| Revenue | 208.702 | 236.714 | 226.0967 | 187.9456 | 158.5678 |
| Expenses | 185.635 | 202.563 | 200.3023 | 168.8671 | 150.0353 |
| ROE(%) | 11.39 | 13.55 | 9.93 | 8.65 | 3.99 |
Corporate Action
| XD-Date | Dividend-Amount | Dividend-% | Dividend Yield(%GE) | Price on that day |
|---|---|---|---|---|
| 06 Sep 2024 | 5 | 100 | 0.88 | 351.15 |
| 21 Aug 2023 | 5 | 100 | 0.88 | 352.9 |
| 29 Oct 2021 | 4 | 80 | 0.88 | 162.15 |
| 22 Sep 2021 | 1 | 20 | 0.88 | 157.65 |
| 22 Sep 2020 | 0.5 | 10 | 0.88 | 35.15 |
| 20 Sep 2019 | 0.25 | 5 | 0.88 | 27.1 |
| 18 Sep 2018 | 0.1 | 2 | 0.88 | 26.7 |
| 21 Sep 2017 | 0.1 | 2 | 0.88 | 38.4 |
| 21 Sep 2016 | 0.1 | 2 | 0.88 | 33.85 |
| 21 Sep 2015 | 0.1 | 2 | 0.88 | 26.5 |
| 25 Sep 2014 | 0.5 | 10 | 0.88 | 23.65 |
| 25 Sep 2013 | 0.5 | 10 | 0.88 | 9.5 |
| 21 Sep 2012 | 0.5 | 10 | 0.88 | 12.35 |
| 23 Sep 2011 | 0.5 | 10 | 0.88 | 12.55 |
| 21 Sep 2010 | 0.5 | 10 | 0.88 | 23.85 |
| 23 Sep 2009 | 0.25 | 5 | 0.88 | 12.45 |
| 24 Sep 2008 | 0.1 | 2 | 0.88 | 13.4 |
| 21 Sep 2007 | 0.1 | 2 | 0.88 | 16.7 |
| 26 Sep 2006 | 0.1 | 2 | 0.88 | 19.25 |
| 26 Sep 2005 | 1 | 20 | 0.88 | 55.45 |
| 27 Aug 2004 | 0.5 | 10 | 0.88 | 244.25 |
| 30 May 2003 | 3.75 | 37.5 | 0.88 | 81.15 |
| 05 Mar 2002 | 0 | 20 | 0.88 | 111.85 |
| 11 Sep 2001 | 0 | 30 | 0.88 | 330 |
| 0 | 30 | 0.88 | 199 |
Peers
Other companies within the same industry or sector that are comparable to Jagsonpal Pharmaceuticals Ltd
| Company | Price | Price (% change) | pe(x) | EV/EBITDA(x) | ROE(%) | ROCE(%) |
|---|---|---|---|---|---|---|
| Albert David Ltd | 840.85 | 0.23 | 11.87 | 132.69 | 1321.50 | 1.37 |
| Lotus Eye Hospital and Institute Ltd | 81.36 | 2.94 | 339.00 | 483.51 | 14.01 | 0.61 |
| Vaishali Pharma Ltd | 13.72 | -0.15 | 457.33 | 249.22 | 2.76 | 0.00 |
| Astec Lifesciences Ltd | 693.05 | -1.61 | 0.00 | 455.91 | -687.11 | 0.00 |
Company Info
1995 - The Company is well poised to venture into new areas of activity which will propel it into achieving its projected goals. 1998 - The company is all set to realise it's laid-out expansion plans and gain substantially, both in sales volume and profits, with its proposed new product introductions, in the year. 1999 - The Company launched/re-launched a few products, which have been well received in the market. - The Company raised funds to the tune of Rs.5 crores through issue of 5,00,000 16% Non-Convertible Secured Debentures of Rs. 100 each to Life Insurance Corporation of India, General Insurance Corporation of India (GIC) and four subsidiaries of GIC. - The company is manufacturing off-patent drugs, where the entry barriers are relatively low. - The company has entered into tie-ups to make a range of anti-oxidants and hormones which are expected to be launched in 1999-2000. 2000 - The Company is having in-house share transfer and related facilities at the Registered office New Delhi. The Company is entering into an agreement with NSDL and CDSL for dematerialisation. 2004 -Company has issued a bonus shares in the ratio of 3:1. 2011 -The company has recommended a dividend of Rs. 0.50 per equity shares. 2013 -The company has recommended a dividend of Rs. 0.50 per equity shares. -Mr. Raj Kumar Kapoor has been appointed as Compliance officer cum Company Secretary of the company. 2014 -The company has recommended dividend of Rs. 0.50/- per Equity share. 2024 -The Company has informed regarding Acquisition for signing Business Transfer Agreement for the purchase of India & Bhutan business of Yash Pharma Laboratories Pvt.Ltd. -The Company Launches MemUp India's First Bioidentical Hormone Replacement Therapy in a Single Pill.
1995 - The Company is well poised to venture into new areas of activity which will propel it into achieving its projected goals. 1998 - The company is all set to realise it's laid-out expansion plans and gain substantially, both in sales volume and profits, with its proposed new product introductions, in the year. 1999 - The Company launched/re-launched a few products, which have been well received in the market. - The Company raised funds to the tune of Rs.5 crores through issue of 5,00,000 16% Non-Convertible Secured Debentures of Rs. 100 each to Life Insurance Corporation of India, General Insurance Corporation of India (GIC) and four subsidiaries of GIC. - The company is manufacturing off-patent drugs, where the entry barriers are relatively low. - The company has entered into tie-ups to make a range of anti-oxidants and hormones which are expected to be launched in 1999-2000. 2000 - The Company is having in-house share transfer and related facilities at the Registered office New Delhi. The Company is entering into an agreement with NSDL and CDSL for dematerialisation. 2004 -Company has issued a bonus shares in the ratio of 3:1. 2011 -The company has recommended a dividend of Rs. 0.50 per equity shares. 2013 -The company has recommended a dividend of Rs. 0.50 per equity shares. -Mr. Raj Kumar Kapoor has been appointed as Compliance officer cum Company Secretary of the company. 2014 -The company has recommended dividend of Rs. 0.50/- per Equity share. 2024 -The Company has informed regarding Acquisition for signing Business Transfer Agreement for the purchase of India & Bhutan business of Yash Pharma Laboratories Pvt.Ltd. -The Company Launches MemUp India's First Bioidentical Hormone Replacement Therapy in a Single Pill.
Read More
Parent Organisation
Jagsonpal Pharmaceuticals Ltd.
Founded
17/08/1978
Managing Director
Mr.Manish Gupta
NSE Symbol
JAGSNPHARMEQ
FAQ
The current price of Jagsonpal Pharmaceuticals Ltd is ₹ 227.46.
The 52-week high for Jagsonpal Pharmaceuticals Ltd is ₹ 235.37 and the 52-week low is ₹ 226.95.
The market capitalization of Jagsonpal Pharmaceuticals Ltd is currently ₹ 1511.21. This value can fluctuate based on stock price movements and changes in the number of shares outstanding.
To buy Jagsonpal Pharmaceuticals Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.
To invest in Jagsonpal Pharmaceuticals Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase Jagsonpal Pharmaceuticals Ltd shares.
The CEO of Jagsonpal Pharmaceuticals Ltd is Mr.Manish Gupta, who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.
